Status and phase
Conditions
Treatments
About
This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
138 participants in 1 patient group
Loading...
Central trial contact
Yang Wu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal